问题二.关于国外业务。年报显示，公司采用直销模式开展境内外销售。2023 年，国外地 区营业收入为 1.42 亿元，同比下降 25.56%，占主营业务收入的比重为 48.56%，国外地区 毛利率为 89.10%，高于国内地区毛利率 15.27 个百分点。 请你公司：(1)结合2023年国外前五大客户的主要情况，包括但不限于成立时间、销售内容 、销售金额及合作历史等，说明上市以来国外主要客户的变动情况及变动原因。(2)结合 2023年国外销售收入的区域分布、下游行业分布，说明上市以来国外销售的区域、行业分布 有无重要变化，如有，请说明原因。（3）结合产品结构、收入构成、同行业可比业务毛利率 等，分析并说明公司国内外销售毛利率差异原因及合理性。请年审会计师说明：（1）对境外 收入的审计程序及其充分性、有效性，包括但不限于境外客户的函证与走访情况，与出口退 税、外管局收汇数据、中信保数据等第三方数据的验证及匹配情况等；（2）公司境外客户应 收账款期后收回情况，未收回账款对应的客户及原因，销售商品、提供劳务收到的现金与收 入是否匹配。 （一） 结合2023年国外前五大客户的主要情况，包括但不限于成立时间、销售内容、销 ...

Summary of the Conference Call for JianKai Technology Company Overview - **Company Name**: JianKai Technology - **Industry**: Pharmaceutical and Medical Devices Key Points and Arguments Company Performance and Developments - The company has faced challenges in its recent annual and quarterly reports, indicating that the data was not ideal, but there is potential for future growth due to the clearing of special market conditions and the return of excessive technical service fees to initial levels [3][4] - JianKai's first international new drug project has been approved for listing in the U.S., marking a significant milestone in the company's international innovation efforts [3][4] - Two PEGylated drugs supported by JianKai received market approval in China in 2023, with several other late-stage clinical projects also in the pipeline [6][8] Research and Development - The company maintained a high level of R&D investment, totaling over 57 million, which accounts for 17.079% of sales revenue, indicating a commitment to innovation despite market challenges [8] - JianKai is actively pursuing clinical trials for various products, including a compound sodium hyaluronate solution, with expectations to complete clinical trials by Q4 2024 [10] Market Strategy and Future Outlook - The company is focusing on expanding its application of innovative materials and medical devices, with new applications emerging in 2023 [7][8] - JianKai is optimistic about the future of its medical aesthetics segment, with ongoing clinical trials and product approvals expected to drive growth [17][19] - The company is also exploring new customer relationships and maintaining communication with existing clients to adapt to market demands [29][38] Competitive Landscape - The competitive landscape in the PET market is evolving, with domestic pricing having a more significant impact than international pricing [34][35] - The company is adjusting its pricing strategies based on market dynamics and customer negotiations, ensuring that gross margins are maintained [35] Clinical Trials and Product Development - The company is in the process of advancing its clinical trials for various products, including small cell lung cancer treatments, with ongoing preparations for patient enrollment [25][27] - There is a focus on ensuring compliance and thoroughness in clinical trial processes, which can be time-consuming but is essential for product integrity [16][28] Investor Communication - The company emphasizes the importance of transparency and communication with investors, assuring them that updates will be provided as significant developments occur [26][39] - There is a recognition of the need for patience from investors regarding the timelines for product approvals and clinical trial results [20][21] Additional Important Information - The company is actively working on multiple fronts, including the development of innovative medical devices and pharmaceuticals, while also managing existing product lines and customer relationships [41][42] - The management is committed to maintaining a balance between innovation and operational efficiency, ensuring that the company remains competitive in a challenging market environment [11][12][41]

Summary of Conference Call Company or Industry Involved - The document does not specify a particular company or industry, but it references a research report from Guosheng Securities. Core Points and Arguments - The opinions expressed by the guest speakers are personal views and do not represent the official stance of Guosheng Securities [1] - The content of the conference call is subject to the terms and conditions set by Guosheng Securities, including restrictions on recording and distribution [1] Other Important but Possibly Overlooked Content - The document emphasizes the legal rights of Guosheng Securities to pursue legal action against any violations of their terms [1]

证券代码：688356 证券简称：键凯科技 公告编号：2024-024 本次利润分配方案经公司 2024 年5 月 24 日的2023 年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2023 年年度 北京键凯科技股份有限公司 2023 年年度权益分派实 施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2024/6/17 | 2024/6/18 | 2024/6/18 | 一、 通过分配方案的股东大会届次和日期 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 （北京键凯科技股份有限公司回购专用证券账户除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章 及其他规范性文件以及《公司 ...

北京市中伦律师事务所 关于北京键凯科技股份有限公司 差异化权益分派事项的 法律意见书 二〇二四年五月 北京市中伦律师事务所 1. 本所律师已得到公司如下保证：即公司业已向本所律师提供了本所律师 认为制作法律意见书所必需的原始书面材料、副本材料或口头证言等，其所提供 的文件资料的副本或复印件与正本或原件一致，且该等文件资料的签字与印章都 法律意见书 关于北京键凯科技股份有限公司 差异化权益分派事项的 法律意见书 致：北京键凯科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受北京键凯科技股份有限公 司（以下简称"公司"）委托，就公司 2023 年年度利润分配涉及的差异化权益分 派事项（以下简称"本次差异化权益分派"）出具法律意见书。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股份回购规则》（以 下简称"《回购规则》"）、《上海证券交易所上市公司自律监管指引第 7 号——回 购股份》（下称"《回购指引》"）等相关法律法规、规范性文件以及《北京键凯科 技股份有限公司章程》（以下简称"《公司章程》"）的规定出具。 为出 ...

Group 1: Product Development - The injectable cross-linked sodium hyaluronate gel project is currently undergoing technical review, with all inspections passed so far, but the expected registration time is still uncertain [1][2] - The injectable sodium hyaluronate composite solution project has completed clinical enrollment and is currently in the follow-up stage [2] Group 2: Market Strategy - The company plans to first obtain approval for the injectable cross-linked sodium hyaluronate gel and the injectable sodium hyaluronate composite solution, with potential future development of more functional medical device product lines based on these two products [2] - The company will not establish its own sales team, and the specific sales model is still under evaluation [2] Group 3: Innovation and Competition - The company is developing a novel three-component lipid nanoparticle delivery system, which has independent intellectual property advantages [2] - The development of nucleic acid drugs related to synthetic biology is a new application scenario for the company's drug delivery platform [2] - The company focuses on early innovative projects and aims to establish long-term cooperation with clients to address homogenization competition [2] - The company plans to enrich its product line, develop new materials and delivery platforms, and explore new market directions [2] - The company actively communicates with international clients to alleviate concerns [2] Group 4: Financial Insights - The inconsistency between revenue and cash inflow in Q1 2024 is mainly related to the payment collection cycle [3]

证券代码：688356 证券简称：键凯科技 公告编号：2024-022 北京键凯科技股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/22 | | --- | --- | | 回购方案实施期限 | 2024/2/21~2025/2/20 | | 预计回购金额 | 万元~2,000 万元 1,000 | | 回购用途 | 用于员工持股计划或股权激励 | | 累计已回购股数 | 万股 10.5614 | | 累计已回购股数占总股本比例 | 0.1742% | | 累计已回购金额 | 万元 782.04 | | 实际回购价格区间 | 元/股~75.05 元/股 72.42 | 一、 回购股份的基本情况 2024 年 2 月 21 日，北京键凯科技股份有限公司（以下简称"公司"）召开第 三届董事会第七次会议，审议通过了《关于以集中竞价交易方式回购公司股份方 案的议案》，同意公司使用不低于人民币 1000 万元（含），不超过人 ...

北京市中伦律师事务所 关于北京键凯科技股份有限公司 2023 年年度股东大会之 法律意见书 二〇二四年五月 北京市中伦律师事务所 关于北京键凯科技股份有限公司 2023 年年度股东大会之 法律意见书 致：北京键凯科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受北京键凯科技股份有限公 司（以下简称"公司"）委托，指派陆群威律师和谢金莲律师列席了公司 2023 年 年度股东大会（以下简称"本次股东大会"），就本次股东大会的相关事项进行见 证，并出具法律意见书。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以 下简称"《股东大会规则》"）等相关法律法规、规范性文件以及《北京键凯科技 股份有限公司章程》（以下简称"《公司章程》"）的规定出具。 为出具本法律意见书，本所律师审查了公司提供的与本次股东大会有关的文 件、资料及相关材料。本所律师出具本法律意见书基于公司向本所律师提供的一 切原始文件、副本材料均真实、准确、完整、有效，不存在虚假记载、误导性陈 述或者重大遗漏，有关文件的印章和签字均真实、有效， ...

证券代码：688356 证券简称：键凯科技 公告编号：2024-021 北京键凯科技股份有限公司 2023 年年度股东大会决议公告 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 24 | | --- | --- | | 普通股股东人数 | 24 | | 2、出席会议的股东所持有的表决权数量 | 25,652,368 | | 普通股股东所持有表决权数量 | 25,652,368 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 42.3942 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 42.3942 | 注:截至本次股东大会股权登记日，公司回购专用证券账户中股份数为 105,614 股，该等 回购股份不享有股东大会表决权。 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2 ...

Investment Rating - The report assigns a "Buy" rating to the company, indicating an expectation that the company's stock price will exceed the benchmark index by more than 20% within the next 6-12 months [42][46]. Core Insights - The report highlights the high barriers to entry in the polyethylene glycol (PEG) modification technology sector, with few companies globally possessing advanced synthesis and modification capabilities [1]. - The domestic PEG industry is still in its early stages compared to international counterparts, with ongoing exploration and development [2]. - The global PEG-modified drug market has reached a certain scale, while the domestic market is just beginning to develop [7]. - The report notes a significant increase in the number of companies engaged in PEG-modified drug research and clinical trials in China, with approximately 45+ companies reported as of December 31, 2023 [11]. - The report discusses the broad prospects for PEG-modified drugs in light of the ongoing national procurement policies, which have led to substantial price reductions in generic drugs [12]. Summary by Sections Company Overview - The report provides a detailed overview of several companies involved in PEG technology, including Xiamen Sinobang Biological Technology Co., Ltd., Jiaxing Bomei Biotechnology Co., Ltd., and Beijing Kaizheng United Pharmaceutical Technology Co., Ltd., highlighting their focus areas and product offerings [5]. Market Dynamics - The report outlines the competitive landscape of the long-acting drug market, emphasizing the limited number of approved long-acting G-CSF products in China, which presents opportunities for growth [54][55]. - It also discusses the increasing sales of overseas medical device products, with a reported growth of 21.48% year-on-year in 2023 [33]. Financial Projections - The company is projected to achieve revenues of CNY 368 million, CNY 459 million, and CNY 559 million from 2024 to 2026, respectively, with net profits expected to reach CNY 142 million, CNY 178 million, and CNY 220 million in the same period [42][72]. - The report anticipates a gradual improvement in the company's performance, driven by the launch of new products by downstream clients [42]. Product Development - The report highlights the successful clinical trial progress of the PEG-modified irinotecan and the development of new medical aesthetic products, indicating a promising future for the company's product pipeline [34][39]. - It also mentions the company's proprietary PEG cross-linked sodium hyaluronate gel project, which has received regulatory acceptance and is advancing through clinical trials [39][68].